Haleos Labs Limited (NSE: HALEOSLABS) has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026, as approved by its Board of Directors at a meeting held on May 29, 2026. The company simultaneously submitted its financial results for the quarter ended June 30, 2026, to the Exchange on August 5, 2026.

Dividend Details

With no live trade data currently available for HALEOSLABS on the Exchange, a precise dividend yield calculation against the prevailing market price cannot be determined at this time. Investors should compute yield as ₹1.50 divided by the current market price once trading resumes or data is available.

Dividend History: Remarkable Consistency Since FY19

The ₹1.50 per share payout is notable not merely for its quantum but for its extraordinary consistency. NSE records show that Haleos Labs, formerly operating as SMS Lifesciences India Limited before its rebranding, has declared an identical ₹1.50 per equity share dividend every single year from FY2019 through FY2026, covering at least seven consecutive financial years without a single break or revision.

This unbroken streak of identical payouts across multiple business cycles, including the disruption years of FY2020 and FY2021, reflects a deliberate and stable capital return policy. Notably, there is no record of a dividend declaration for FY2020 in the available NSE announcements, which investors may wish to verify independently.

Company Background and Rebranding Context

Haleos Labs Limited, carrying ISIN INE320X01016, is the rebranded entity of SMS Lifesciences India Limited, a pharmaceutical company previously focused on active pharmaceutical ingredients and drug intermediates. The name change to Haleos Labs signals a strategic repositioning, though the company has retained its historical dividend commitment through the transition. The Q1 FY27 financial results submission on August 5, 2026, marks one of the first major regulatory filings under the new corporate identity.

What the Announcement Means for Investors

The flat dividend trajectory over seven years carries a dual interpretation for income-focused investors. On one hand, the consistency demonstrates management's commitment to returning capital even through challenging operating environments. On the other hand, the absence of any dividend growth over this period, despite inflationary pressures eroding real returns, means the effective purchasing power of the payout has declined year on year.

Without current price, PE ratio, sector PE, delivery percentage, or 52-week range data available from the Exchange feed, a complete valuation and trading-activity assessment cannot be provided at this stage. Investors tracking HALEOSLABS are advised to monitor the NSE portal for updated trade data alongside the Q1 FY27 results, which were submitted to the Exchange on August 5, 2026, and may provide additional clarity on earnings trajectory relative to the sustained ₹1.50 dividend commitment.